98%
921
2 minutes
20
Background And Aim: N-terminal pro B-type natriuretic peptide (NT-proBNP) is a key biomarker for assessing cardiac function and hemodynamic stress. However, clinical guidelines lack clear recommendations on its utility in populations at risk of heart failure (HF), including those with hypertension, diabetes, or dyslipidemia. This study aimed to characterize the distribution of NT-proBNP levels in HF-prone individuals and establish population-specific screening thresholds.
Methods And Results: A cross-sectional analysis was conducted across three cohorts: 2421 patients with HF risk factors (hypertension, diabetes, or dyslipidemia), 625 patients with congestive HF, and 833 healthy controls. NT-proBNP levels were stratified by cardiovascular risk categories based on established guidelines. Receiver operating characteristic (ROC) curves were used to determine optimal screening thresholds. Key findings included.
Conclusions: NT-proBNP levels effectively mirror cardiovascular risk stratification in HF-susceptible populations. Adopting risk-stratified reference values (106.0-116.7 pg/mL vs. 124.6 pg/mL in healthy adults) may enhance early HF detection and personalized risk management.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.numecd.2025.104029 | DOI Listing |
Catheter Cardiovasc Interv
September 2025
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Patent foramen ovale (PFO) has been identified as a potential risk factor for cryptogenic stroke (CS). Although transesophageal echocardiography (TEE) is considered the gold standard for PFO detection, false-negative results remain a clinical concern, particularly in CS patients with high suspicion of PFO-related etiology.
Aims: To evaluate the clinical utility of transcatheter PFO exploration (TPFOE) in CS patients with negative TEE findings but high suspicion of PFO-related etiology.
BMC Cardiovasc Disord
September 2025
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Sociology and Rehabilitation Science, Charitéplatz 1, 10117, Berlin, Germany.
Background: Myocardial infarctions (MI) significantly contribute to the global disease burden and are often followed by psychological conditions such as depression, anxiety, and posttraumatic stress disorder (PTSD). These are frequently underrecognized and insufficiently addressed in clinical care. This study aims to investigate the psychosocial impact of MI, identify risk factors for psychological burden following an MI, and gain insight into the perceived psychological care during hospitalization.
View Article and Find Full Text PDFAlzheimers Dement
September 2025
Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Introduction: Mild cognitive impairment (MCI) represents a transitional stage between normal aging and dementia. We investigate associations among cardiovascular and metabolic disorders (hypertension, diabetes mellitus, and hyperlipidemia) and diagnosis (normal; amnestic [aMCI]; and non-amnestic [naMCI]).
Methods: Multinomial logistic regressions of participant data (N = 8737; age = 70.
Ren Fail
December 2025
Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
The Grams model, designed to predict adverse event risks in advanced chronic kidney disease (CKD) patients, was evaluated in a Chinese cohort of 1,333 patients with eGFR below 30 mL/min/1.73 m. The model demonstrated moderate to good discrimination across outcomes, performing well in predicting kidney replacement therapy (KRT) but overestimating the risks of cardiovascular disease (CVD) and mortality.
View Article and Find Full Text PDFJ Nephrol
September 2025
Department of Cardiovascular Sciences, University of Leicester, John Walls' Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK.
Background: Individuals with kidney failure experience elevated cardiovascular risk, potentially worsened by the presence of sleep disordered breathing. Despite this association, prevalence of sleep apnoea, and evidence for effective treatments are poorly understood in people with kidney failure. This review examines sleep apnoea prevalence, types of sleep apnoea, and treatment interventions in people with kidney failure receiving dialysis.
View Article and Find Full Text PDF